Ashley Gallagher, Editor

New study results focus on blood pressure, blood sugar, and cholesterol levels; body mass index; and smoking status when individuals have bipolar or schizoaffective disorder or schizophrenia.

Investigators also identified that a polymerase inhibitor with a unique modification largely resists its removal from the RNA by the exonuclease.

Thirty minutes of day of movement, such as walking, can help break the cycle of inflammation that causes symptoms even 6 months later.

Analysis of the trial show that intensifying the chemotherapy regimen allowed for elimination of radiation in 90% of pediatric patients with T-cell acute lymphoblastic leukemia.

Results of an excess-deaths analysis show that 18.2 million individuals have likely died as a result of the pandemic.

Pharmacy Times will be covering the upcoming Hematology and Oncology Pharmacy Association (HOPA) Association Annual Conference live in Boston, Massachusetts, taking place March 30 through April 2.

Simulations of disease spread show that wearing masks for at least 2 weeks after achieving goal of a minimum of 70% population coverage saves money and reduces deaths and hospitalizations.

Moderna expects to enroll approximately 375 participants in about 20 sites across the United States.

Just culture framework helps to balance safety and accountability in medication error by identifying the root cause without blaming an individual.

Pharmacy leadership remaining mindful, connected, and engaged is crucial to support the mental health needs of their staff.

Opening the door for communication in a nonjudgmental manner is essential for pharmacists to counsel patients on cannabis use.

A presentation at the American Pharmacists Association Annual Meeting 2022, highlighted potential innovations for community pharmacies.

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

Trial of empagliflozin (Jardiance) in adults with chronic kidney disease will end early based on a recommendation from the trial’s Independent Data Monitoring Committee based on clear positive efficacy.

Agency hopes green light for complex drug device combination improves competition and access more affordable medications.

The medications may also help tackle the global problem of antibiotic resistance, investigators say.

Investigators call for routine monitoring of vaccination effectiveness as the pandemic continues to evolve.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

The median survival time of patients was 12 months compared with 7 in the control group, the analysis demonstrates.

Analysis assessing data from the world’s largest twin registry also finds evidence that genetic factors for strong headaches may differ between men and women.

Individuals with multiple sclerosis should follow vaccine guidelines before starting disease-modifying therapies, case study results show.

The risk of developing acute renal failure and septic shock were higher for individuals with necrotizing soft-tissue infections treated with immunoglobulins, investigators say.

The medication is the first oral therapy specifically to treat the virus evaluated in a pediatric clinical trial.

Prevalence is also linked to mental health conditions and substance use disorders, according to analysis.

These individuals, who were also more likely to require treatment in the intensive care unit, should get their vaccines and booster shots, investigators say.

Headache disorders most affect the ability to do physical labor, decision-making skills, and memory, investigators from the University of Copenhagen say.

Investigators advise third short for patients with weakened immune system, especially organ transplant recipients.

Although the risks are still, individuals with a history of migraines should be aware of and consult with their physicians, investigators say.

Phase 3 TROPiCS-02 study continues to follow patients for overall survival, a key secondary endpoint.

Effectiveness is estimated at approximately 91% against any SARS-CoV-2 infection and approximately 85% effective against asymptomatic infection, analysis results show.